Drug Profile
Research programme: prodrug therapeutics - Sanofi
Alternative Names: TransCon Hydrogel GLP-1; TransCon Hydrogel insulin; TransCon Hydrogel paliperidone; TransCon Hydrogel pramipexole; TransCon PEG interferon αLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Ascendis Pharma
- Class Benzothiazoles; Glucagon-like peptides; Insulins; Interferons; Isoxazoles; Polyethylene glycols
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists; Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Interferon alpha stimulants; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders; Diabetes mellitus; Hepatitis C
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Diabetes-mellitus in Germany (SC, Controlled release)
- 24 Apr 2019 Preclinical development is ongoing in Diabetes mellitus in Germany (SC)
- 28 Sep 2018 No recent reports of development identified for preclinical development in CNS-disorders in Germany (SC, Controlled release)